PMID- 20621192 OWN - NLM STAT- MEDLINE DCOM- 20110224 LR - 20181201 IS - 1095-9130 (Electronic) IS - 1046-2023 (Linking) VI - 52 IP - 4 DP - 2010 Dec TI - Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. PG - 352-8 LID - 10.1016/j.ymeth.2010.07.005 [doi] AB - Cancer diagnosis can be a complex process, which takes consideration of histopathological, clinical, immunophenotypic, and genetic features. Since non-random chromosomal translocations are specifically involved in the development of various cancers, the detection of these gene aberrations becomes increasingly important. In recent years, break-apart (or split-signal) fluorescence in situ hybridization (FISH) has emerged as an advantageous technique to detect gene translocations on tissue sections. However, FISH assays are technically challenging and require specialized fluorescence microscopes. Furthermore, the FISH signal is not stable for long term archiving due to photo bleaching. Our objective was to demonstrate the feasibility of brightfield break-apart in situ hybridization (ba-ISH) for anaplastic lymphoma kinase (ALK) and mucosa-associated lymphoid tissue translocation protein 1 (MALT1) genes as models. ALK or MALT1 break-apart probes were labeled with digoxigenin (DIG) or 2,4-dinitrophenyl (DNP) on both sides of a known gene breakpoint region and the hybridization sites were visualized with the combination of alkaline phosphatase (AP)-based blue and red detection. Therefore, normal genes are detected as purple dots by mixing blue and red colors while translocated genes are detected as isolated blue or red dots. Formalin-fixed, paraffin-embedded tonsil was used as control for the co-localized 5' and 3' probes. Gene translocations of ALK or MALT1 were detected as separate blue and red dots on ALCL and MALT lymphoma cases. Thus, ISH analyses of gene translocations can be conducted with a regular light microscope and the long term archiving of break-apart ISH slides can be achieved. CI - Copyright (c) 2010 Elsevier Inc. All rights reserved. FAU - Nitta, Hiroaki AU - Nitta H AD - Office of Medical Affairs, Ventana Medical Systems, Inc., 1910 E Innovation Park Drive, Tucson, AZ 85755, USA. hiro.nitta@ventana.roche.com FAU - Zhang, Wenjun AU - Zhang W FAU - Kelly, Brian D AU - Kelly BD FAU - Miller, Melanie AU - Miller M FAU - Pestic-Dragovich, Lidija AU - Pestic-Dragovich L FAU - Bieniarz, Christopher AU - Bieniarz C FAU - Vasicek, Thomas J AU - Vasicek TJ FAU - Marafioti, Teresa AU - Marafioti T FAU - Rimsza, Lisa AU - Rimsza L FAU - Grogan, Thomas M AU - Grogan TM LA - eng PT - Journal Article DEP - 20100716 PL - United States TA - Methods JT - Methods (San Diego, Calif.) JID - 9426302 RN - 0 (DNA Probes) RN - 0 (Neoplasm Proteins) RN - EC 2.7.10.1 (ALK protein, human) RN - EC 2.7.10.1 (Anaplastic Lymphoma Kinase) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) RN - EC 3.4.22.- (Caspases) RN - EC 3.4.22.- (MALT1 protein, human) RN - EC 3.4.22.- (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein) SB - IM MH - Anaplastic Lymphoma Kinase MH - Caspases/*genetics MH - DNA Probes MH - Humans MH - In Situ Hybridization/*methods MH - Lymphoma, B-Cell, Marginal Zone/genetics MH - Lymphoma, Large-Cell, Anaplastic/genetics MH - Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein MH - Neoplasm Proteins/*genetics MH - Protein-Tyrosine Kinases/*genetics MH - Receptor Protein-Tyrosine Kinases MH - Translocation, Genetic/genetics EDAT- 2010/07/14 06:00 MHDA- 2011/02/25 06:00 CRDT- 2010/07/13 06:00 PHST- 2010/06/25 00:00 [received] PHST- 2010/07/05 00:00 [accepted] PHST- 2010/07/13 06:00 [entrez] PHST- 2010/07/14 06:00 [pubmed] PHST- 2011/02/25 06:00 [medline] AID - S1046-2023(10)00186-6 [pii] AID - 10.1016/j.ymeth.2010.07.005 [doi] PST - ppublish SO - Methods. 2010 Dec;52(4):352-8. doi: 10.1016/j.ymeth.2010.07.005. Epub 2010 Jul 16.